ityriasis lichenoides et varioliformis acuta (PLEVA) is a cutaneous disorder of unknown etiology and characterized by a generalized eruption of acute onset, consisting of papular lesions that undergo central vesiculation which may ulcerate and resolve with hemorrhagic crusts.
ityriasis lichenoides et varioliformis acuta (PLEVA) is a cutaneous disorder of unknown etiology and characterized by a generalized eruption of acute onset, consisting of papular lesions that undergo central vesiculation which may ulcerate and resolve with hemorrhagic crusts. 1, 2 Although descriptions of this disorder had been made many times previously, term "PLEVA" was first described in 1925 by Habermann. 3 PLEVA occurs predominantly in the second or third decades of life and it is uncommon in childhood. There is a male predominance. 4 The disease starts on the trunk with erythematous papules that develop crusts, vesicles, pustules or erosions, then spontaneously regresses within a few weeks. 3, 4 Varioliform scars and postinflammatory hyper-or hypopigmentation may result. 3 The eruption may be asymptomatic or sometimes accompanied by itching, fever and malaise. 1 There are three major pathogenic theories of PLEVA: an inflammatory reaction triggered by infectious agents; an inflammatory response secondary to a T-cell dyscrasia and an immune complex-mediated hypersensitivity vasculitis. 3 A number of physicians suspect an infectious etiology such as Epstein-Barr virus, Toxoplasma gondii and Human immunodeficiency virus since the disease appears rapidly and favors younger patients. 2, 3 Several reports have demonstrated clonal T-cell receptor rearrangements from patient specimens, suggesting that PLEVA is a lymphoproliferative disorder involving T-cell subtypes, despite its clinically benign course and the absence of morphologically atypical cells in the skin lesions. 4 PLEVA is the prototypic disease featuring lymphocytic vasculitis, except that fibrin deposition is not seen. Lymphoid atypia is not a standard feature of PLEVA. All cases of PLEVA show interface dermatitis. There is exocytosis, parakeratosis and extravasation of erythrocytes. Epidermal damage range from intercellular and extracellular edema, to extensive keratinocyte necrosis, vesicles, pustules and ulcers. Immunohistochemical stainings are mostly positive for CD8 and negative for CD4 and CD30. The di ag no sis of PLE VA is ma de by the cor rela ti on of cli ni cal fe a tu res and le si o nal his to pat hology. The most chal len ging di se a se is lympho mato id pa pu lo sis. However, it can be ea sily dif fe renti a ted by its cli ni cal fin dings (pa pu les can de ve lop in to no du les, tu mors, pla qu es), du ra ti on of di se a se (many ye ars) and his to lo gi cal fin dings (aty pi cal nonly mpho id cell, CD30 po si ti ve) from PLE VA. 3 The dif fe ren ti al di ag no sis of PLE VA al so inc lu des chic ken pox, Gi a not ti-Cros ti Syndro me (pa pu lar acro der ma ti tis of child ho od), lic hen pla nus, pit yri a sis ro se a, gut ta te pso ri a sis, art hro pod bi te, sca bi es, disse mi na ted Her pes zos ter, drug erup ti on, pri mary HIV in fec ti on, se con dary syphi lis, vas cu li tis and viral exant hems (Tab le 1).
The re are se ve ral dif fe rent the ra pe u tic mo dali ti es that ha ve be en used in PLE VA. When pru ritus is se ve re, to pi cal cor ti cos te ro ids and an ti his ta mi nes may pro vi de sympto ma tic re li ef wit ho ut chan ging the di se a se co ur se. In adult pa tients, ad mi nis tra ti on of met hot re xa te and oral tetracy cli ne has led to go od re sults; but, the se me di ca ti ons are inap prop ri a te for the first-li ne treat ment of chil dren. Eryt hromy cin se ems to be the pre fer red ini ti al tre at ment for chil dren. 3 Ho we ver, the da ta abo ut the res pon se to oral eryt hromy cin in the chil dren with PLE VA is con tro ver si al and the response ra tes va ri es bet we en 25-73%. 5 In many of the se ca ses, the rash re tur ned if the me dici ne was ta pe red to o ra pidly. Tet racy cli ne has been re por ted to be of va lu e as well. 3, 5 Anot her oral me di ca ti on suc cess fully used in the tre at ment of PLE VA is azit hromy cin. The re are a few re ports with go od cli ni cal re sults with the use of oral azithromy cin 500 mg/day for thre e con se cu ti ve days every we ek. 2 In our pa ti ent, oral eryt hromy cin 4 x 250 mg/day and to pi cal ste ro ids were ad mi nis te red. Af ter fo ur we eks, no cli ni cal res pon se was ex pe rien ced by the pa ti ent. As a con se qu en ce, a new therapy with oral azit hromy cin (500 mg/day for thre e con se cu ti ve days every we ek) was ad mi nis te red. Af ter thre e co ur ses of azit hromy cin, the erup ti ons ra pidly im pro ved. Af ter eight we eks, the pa ti ent comp le tely re co ve red and the tre at ment stop ped. Af ter two months of fol low-up, the re was no recur ren ce (Fi gu re 1). In ad di ti on, a number of reports in di ca te the be ne fits of ul tra vi o let (UV) the rapy for PLE VA. PU VA and UVB ha ve be en used with var ying deg re es of suc cess. Arıcan ve ark. Deri ve Zührevi Hastalıkları de ve lop af ter a few we eks, and many ca ses cle ar wit hin six months. In ge ne ral, the im me di a te progno sis is sa id to be bet ter when the on set is acu te and the le si ons in suc ces si ve crops. 3 Alt ho ugh the conc lu si on was not con fir med by a sub se qu ent in ves tiga ti on, a smal ler study com pa ring adults and chil dren fo und that the di se a se ten ded to run a longer co ur se in chil dren, with gre a ter ex tent of le sions, mo re pig men ta ti on, and po or res pon se to con ven ti o nal tre at ment. 5 We re port a child with PLE VA un res pon si ve to eryt hromy cin, and ra pidly re sol ved with thre e co ur ses of azit hromy cin. The res pon se of our pa ti ent to azit hromy cin can be expla i ned by im pro ved syste mic ab sorp ti on, en han ced pe net ra ti on in to tis su es, and the lon ger half-li fe of azit hromy cin over eryt hromy cin. 2 Of co ur se, the pos si bi lity of spon ta ne o us re so lu ti on must be en terta i ned. Ho we ver, the ti ming of re so lu ti on af ter starting azit hromy cin tre at ment af ter per sis ten ce of di se a se with ot her tre at ment is sug ges ti ve of the bene fit of azithromycin ran do mi zed do ub le-blind place bo con trol led tri als are ne e ded to fully elu ci da te the be ne fit of this an ti bi o tic in this skin di se a se.
FIGURE 1:
The eruptions had almost disappeared after the therapy.
